RESUMO
OBJECTIVE: To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in acute PE. METHODS: This was a randomized, placebo-controlled, double blind trial conducted at four academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50â¯parts per million nitrogen (placebo) or oxygen plus 50â¯ppm NO for 24â¯h. The primary composite endpoint required a normal RV on echocardiography and a plasma troponin T concentration <14â¯pg/mL. The secondary endpoint required a blood brain natriuretic peptide concentration <90â¯pg/mL and a Borg dyspnea scoreâ¯≤â¯2. The sample size of Nâ¯=â¯76 tested if 30% more patients treated with NO would achieve the primary endpoint with 80% power and alphaâ¯=â¯5%. RESULTS: We randomized 78 patients and after two withdrawals, 38 were treated per protocol in each group. Patients were well matched for baseline conditions. At 24â¯h, 5/38 (13%) of patients treated with placebo and 9/38 (24%) of patients treated with NO reached the primary endpoint (Pâ¯=â¯0.375). The secondary endpoint was reached in 34% with placebo and 13% of the NO (Pâ¯=â¯0.11). In a pre-planned post-hoc analysis, we examined how many patients with RV hypokinesis or dilation at enrollment resolved these abnormalities; 29% more patients treated with NO resolved both abnormalities at 24â¯h (Pâ¯=â¯0.010, Cochrane's Q test). CONCLUSIONS: In patients with severe submassive PE, inhaled nitric oxide failed to increase the proportion of patients with a normal troponin and echocardiogram but increased the probability of eliminating RV hypokinesis and dilation on echocardiography. CLINICAL TRIAL REGISTRATION: NCT01939301.